Established biotech leader with over 20 years’ experience including at OXB and LifeArc driving commercialization to support CGT downstream manufacturing
Michele Pedrocchi PhD appointed as Non-Executive Chair of the Board of Directors
Tozaro, an emerging technology provider in the field of cell and gene therapy manufacturing today announced the appointment of Dr. Jason Slingsby MBA as Chief Executive Officer, effective 22 April 2025. Jason will lead the Company’s long-term strategy, including commercialization of its Smart Polymer technology to enhance downstream manufacturing of viral…
3 July | Babraham Research Campus
What’s Next in Bio Innovation? At ON Helix 2024, we explored how novel therapeutic modalities, biomarker technologies, and TechBio are transforming drug discovery and development and how ecosystems enable scale-up of innovation. ON Helix 2025 will build on these insights, discuss progress and what’s next!
Harnessing the Body’s DefencesFrom protective antibodies to tools that can modulate the immune system, how will the new approaches drive disease prevention and treatment. …
Researchers at the John Innes Centre at Norwich Research Park have helped to solve a historical puzzle that could revolutionise the breeding of the humble pea and other legumes leading to improvements in their nutritional value and lessening the reliance on pesticides.
This landmark work, published in the journal Nature, comes at a time when peas and other legumes are being called upon both as sources of plant protein and as sustainable crops which can fix their own nitrogen. It could result in pea and other legume crops, needing less chemical fertiliser to grow, becoming more economically…
Global drug development consultancy Boyds has appointed a Vice President of Regulatory Affairs in response to growing demand for its specialist services and expertise.
With over 25 years’ experience in medicines development and regulatory affairs, Carmen Vieira joins Boyds to further strengthen its regulatory offering. Previously, Carmen was an independent regulatory science and strategy advisor, supporting the expedited development of medicines for start-ups, biotechs, and big pharma developers. Prior to this, she was Head of Regulatory Affairs & Non-Clinical at the Cell and Gene Therapy…
Isomerase has announced the launch of EvoSelect®, a machine learning-guided enzyme engineering platform designed to accelerate development timelines, enhance performance under industrial conditions, and reduce the cost and complexity of enzyme optimisation. EvoSelect® forms part of Isomerase’s broader IsoZym™ platform, an end-to-end offering that spans protein design, expression, and scale-up.
EvoSelect® harnesses evolutionary information embedded in enzyme families to generate novel sequences with improved properties. By analysing sequence alignments and evolutionary couplings - correlated…
Cambridge, UK, 8th May 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the sale of rights to certain non-Ogluo® products from the portfolio of its Tetris Pharma subsidiary to Aspire Pharma Limited (“Aspire”).
Under the terms of the agreement, Arecor will receive a cash payment of £0.5 million from Aspire in return for both the UK distribution rights to the products and the transfer of existing inventory. There is no separate financial information available in relation to the rights of the non-…
Operational expansion accelerates global distribution capability to increase regional access and technical support
Multiple partnerships establish direct distribution channels in China, Japan, South Korea, Singapore and Israel
Cambridge, UK, and Boston MA, USA, 06 May 2025: Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery™ System, today announced that it has established a distribution network across APAC and the Middle East. Marking a key milestone in the Company’s global commercial strategy, the expansion…
Cambridge, UK, 7th May 2025 / Domainex, a multi-award-winning, integrated drug discovery contract research organisation (CRO), has formally announced the appointment of Hayley French as its new Chief Executive Officer.
Hayley French is a qualified attorney with a background in microbiology and significant experience in the life sciences sector. She possesses a proven track record of fostering growth and innovation, having held leadership positions in multiple pharmaceutical and biotechnology organisations. Her areas of expertise include strategic development, business operations, and…
London, May 7, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.Coramaze Technologies is a pre-commercial medical technology company, focused on developing a novel tricuspid valve repair system, called Tripair™, a minimally invasive solution for treating tricuspid regurgitation (TR). Tripair™ simplifies TR repair through an innovative…
Data presented at Digestive Disease Week in San Diego
Cambridge, UK – 6 May 2025: Microbiotica, a clinical-stage biopharma Company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.
The gut epithelial barrier is compromised in UC patients leading to an exaggerated inflammatory response. MB310 is an LBP comprising eight bacterial species associated with…